Neuland Laboratories
Neuland Laboratories Limited, commonly referred to as Neuland Labs, is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. Founded in 1984, the company has established itself as a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates, catering to both domestic and international markets. With a strong focus on quality and innovation, Neuland Labs offers a diverse range of products, including custom synthesis and contract manufacturing services. The company is renowned for its expertise in complex molecules and has achieved significant milestones, such as obtaining multiple regulatory approvals from global health authorities. Neuland Labs is well-positioned in the market, recognised for its commitment to sustainability and customer-centric solutions. Its strategic operational regions extend across North America, Europe, and Asia, making it a trusted partner for pharmaceutical companies worldwide.
DitchCarbon Score
How does Neuland Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neuland Laboratories's score of 43 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Neuland Laboratories's reported carbon emissions
In 2023, Neuland Laboratories reported total carbon emissions of approximately 60,092,420 kg CO2e, comprising 27,442,350 kg CO2e from Scope 1, 27,245,080 kg CO2e from Scope 2, and 5,406,000 kg CO2e from Scope 3 emissions. This marked a decrease from the previous year's total emissions of about 69,778,000 kg CO2e in 2022. The company has committed to achieving net-zero emissions across all scopes by 2050, with interim targets set to align with the Science Based Targets initiative (SBTi). Neuland Laboratories is actively working towards these long-term climate commitments, reflecting its dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. Over the past few years, Neuland has demonstrated a commitment to reducing its carbon footprint, with significant reductions in emissions observed from 2021 to 2023. The company continues to disclose its emissions data transparently, adhering to industry standards and best practices in climate reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 26,242,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 277,000 | 00,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 52,182,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Neuland Laboratories is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
